Xaira Taps Star Dealmaker to Commercialize AI Drug Discovery Engine

SOUTH SAN FRANCISCO, Calif. – March 26, 2026 – In a significant strategic maneuver, AI-driven life sciences firm Xaira Therapeutics has appointed Dr. Rachel Lane, a renowned biotech dealmaker, as its Senior Vice President of Business Development and Operations. The move signals a clear intent to accelerate the commercialization of its advanced machine learning platform and forge high-stakes partnerships across the pharmaceutical industry.

Reporting to President and COO Jeff Jonker, Dr. Lane is tasked with a critical mission: translating Xaira’s formidable scientific and computational power into tangible business opportunities. Her appointment comes at a pivotal moment for the company, which recently unveiled X-Cell, a groundbreaking virtual cell model, and is backed by an impressive war chest of over $1 billion in capital.

“We are thrilled to have Rachel join Xaira to help drive our dealmaking and further optimize operations across the organization," said Jeff Jonker, President and COO of Xaira Therapeutics. “With her broad experiences as a scientist, Wall Street research analyst, investor, and business development executive, she is a valuable addition to the Xaira team.”

The Architect of Billion-Dollar Deals

Dr. Lane is not just another executive hire; she brings a proven track record of architecting and closing multi-billion-dollar deals that have shaped the biotech landscape. Her most recent tenure as Chief Business Officer at Belharra Therapeutics serves as a powerful testament to her capabilities. There, she was the driving force behind two major platform partnerships that underscore the kind of value Xaira aims to unlock.

In January 2023, she was instrumental in establishing a collaboration with Genentech focused on developing small molecule medicines across oncology, immunology, and neurodegeneration. The deal included a substantial $80 million upfront payment and the potential for over $2 billion in future milestones. More recently, in June 2024, she orchestrated a strategic alliance with Sanofi to discover new therapeutics for immunological diseases, securing up to $40 million in initial payments and nearly $700 million in potential milestone payments.

Her career path reflects a unique blend of scientific rigor and commercial acumen. With a Ph.D. in Molecular Genetics and Cell Biology, postdoctoral training in neurology, and experience as a Wall Street analyst and venture capital investor at Versant Ventures, Dr. Lane possesses a rare, 360-degree perspective on the industry. This diverse background makes her uniquely qualified to bridge the gap between Xaira’s complex AI models and the strategic needs of major pharmaceutical partners.

A Billion-Dollar Bet on Predictive Engineering

Xaira launched from stealth mode in April 2024 with one of the largest initial funding commitments in biotech history, securing over $1 billion in capital. The round, co-led by incubators ARCH Venture Partners and Foresite Capital, drew a who's-who of top-tier investors, including Sequoia Capital and Lightspeed Venture Partners. This massive financial backing underscores immense investor confidence in the company's mission to redefine drug discovery from the ground up.

The company seeks to replace the industry’s traditional, often slow, and failure-prone trial-and-error process with what it calls a “predictive engineering discipline.” The centerpiece of this strategy is X-Cell, its first publicly disclosed virtual cell model. Unveiled this month, X-Cell represents a monumental step toward that goal.

Trained on an unprecedented scale of biological data, X-Cell is designed to accurately predict how human cells will respond to genetic interventions. This capability is a holy grail for drug developers, offering the potential to identify better drug targets, anticipate side effects, and design more effective medicines before ever entering a wet lab.

Decoding Biology with X-Cell

What sets X-Cell apart is not just its size but the nature of the data it learns from. The model is trained on X-Atlas/Pisces, the largest dataset of its kind, containing 25.6 million single-cell transcriptomes from cells that have been deliberately perturbed using CRISPR technology. This focus on causal data—understanding the direct effects of specific interventions—allows the model to learn the fundamental rules of cellular biology, rather than just observing correlations.

The resulting AI, with 4.9 billion parameters in its most advanced form, achieves state-of-the-art performance in predicting the outcomes of genetic experiments it has never seen before. Xaira reports that its model, which uses a novel diffusion-based architecture similar to those powering advanced image-generation AI, outperforms existing models by up to five-fold on key metrics. The model also exhibits power-law scaling, a characteristic of large language models, where performance predictably improves as data and model size increase.

“I could not be more excited to join Xaira at such a pivotal moment in the evolution of AI and drug discovery,” said Dr. Rachel Lane. “From target identification to drug design to patient stratification, Xaira is addressing all three core challenges of drug discovery as both a platform and a pipeline company. Few companies are better positioned than Xaira to shape the next generation of AI models and deploy them to develop differentiated therapeutics.”

Reshaping the Pharma Partnership Landscape

Dr. Lane's appointment is emblematic of a broader shift in the pharmaceutical industry. Facing staggering R&D costs—estimated at over $2.5 billion per approved drug—and lengthy development timelines, large pharma companies are increasingly looking to AI-native biotechs like Xaira for innovation. The global market for AI in drug discovery is projected to grow exponentially, reaching over $17 billion by the early 2030s.

These are not simple vendor-client relationships. The new era of partnerships involves deep, symbiotic collaborations. AI firms bring their powerful predictive platforms and novel biological insights, while established pharmaceutical giants offer vast clinical development experience, regulatory expertise, and global commercial infrastructure. Dr. Lane’s role will be to craft these complex, high-value alliances.

With its elite leadership team, including CEO and former Genentech CSO Marc Tessier-Lavigne, deep financial resources, and a technologically superior platform in X-Cell, Xaira is now perfectly positioned to lead this new paradigm. The hiring of a top-tier dealmaker like Rachel Lane is the final, critical piece of the puzzle, ensuring that the company’s profound scientific potential is translated into a new generation of life-changing medicines.